Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The CPRX news feed on Stock Titan aggregates company announcements, financial updates, scientific disclosures, and investor conference appearances drawn from Catalyst’s own public communications and regulatory filings.
Readers can find earnings and financial result announcements, where Catalyst reports product revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with commentary on operating performance and business outlook. These releases often discuss factors such as organic growth in Lambert-Eaton myasthenic syndrome markets, demand in Duchenne muscular dystrophy centers of excellence, and the impact of generic competition on specific products.
The news stream also features corporate and strategic updates, including authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, and developments in clinical practice guidelines that reference conditions and therapies linked to the company’s portfolio. In addition, Catalyst regularly announces participation in major healthcare and investor conferences, providing insight into how management presents the story behind CPRX to the investment community.
For those following the scientific and patient-focused side of the business, the news includes conference presentations and advocacy initiatives, such as real-world analyses in Duchenne muscular dystrophy, research on Lambert-Eaton myasthenic syndrome, and programs like the Catalyst Advocacy Scholars Summit with academic partners. Investors, analysts, and patients can use this page to monitor how Catalyst’s rare disease strategy, clinical activities, and capital allocation decisions evolve over time. Bookmark this CPRX news page for a centralized view of the company’s key public announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Catalyst Pharmaceuticals (CPRX) is set to release its Q1 2023 financial results after market close on May 10, 2023. A conference call and webcast discussing the results will take place on May 11, 2023, at 8:30 AM ET. The company specializes in developing innovative medicines for rare diseases, with its key product being FIRDAPSE for Lambert-Eaton myasthenic syndrome. Additionally, Catalyst recently acquired U.S. commercial rights to FYCOMPA, an epilepsy treatment approved for patients aged four and older. The company highlights its commitment to patient care and innovative solutions in the biopharmaceutical sector. Investors can access the webcast via their official website, where a replay will be available for 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced the upcoming presentation of four abstracts related to FYCOMPA (perampanel) at the AAN 2023 Annual Meeting in Boston, MA, from April 22-27, 2023. These studies, presented by Eisai, detail the efficacy of FYCOMPA in treating various types of seizures in patients aged four and older, including those with psychiatric histories and Lennox-Gastaut Syndrome. Catalyst's Chief Medical Officer, Gary Ingenito, emphasized the importance of these findings in enhancing understanding of perampanel's therapeutic benefits. FYCOMPA is indicated for partial-onset seizures and primary generalized tonic-clonic seizures. It is available in multiple dosages and is prescribed globally to over 500,000 patients.
Catalyst Pharmaceuticals (CPRX) reported record total net revenues of $214 million for 2022, marking a 52% year-over-year increase. FIRDAPSE® alone contributed $61 million in Q4 2022, up 59% from the previous year. The recent acquisition of FYCOMPA® is projected to enhance EBITDA and EPS in 2023, with total net product revenue guidance between $375 million and $385 million. The company ended 2022 with $298 million in cash, poised for further product portfolio diversification and expansion. Catalyst has strengthened its patent portfolio and continues to drive strategic initiatives, demonstrating strong financial performance and growth potential.